8-K: Cardiff Oncology Announces $40 Million Underwritten Registered Direct Offering

Cardiff Oncology has priced an underwritten offering of 15,384,619 shares of its common stock at $2.60 per share, expected to raise approximately $40 million in gross proceeds.

Summary

• Cardiff Oncology has entered into an underwriting agreement to sell 15,384,619 shares of common stock at a price of $2.60 per share.
• The offering is expected to generate gross proceeds of approximately $40 million before deducting underwriting discounts, commissions, and offering expenses.
• The company plans to use the net proceeds to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer and for working capital and other general corporate purposes.
• The offering is expected to close on or about December 11, 2024, subject to customary closing conditions.
• TD Securities (USA) LLC is acting as the lead book-runner for the offering, with William Blair also acting as book-runner, H.C. Wainwright & Co. as lead manager, and Craig-Hallum as co-manager.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise with strong investor interest. However, it also acknowledges the inherent risks associated with clinical-stage biotech companies.

Positives

• The offering was oversubscribed, indicating strong investor interest.
• The financing includes participation from new mutual fund and healthcare dedicated investors, as well as support from existing investors.
• The funds raised will support the clinical development of onvansertib, a key asset for the company.
• The company has secured multiple underwriters for the offering, including TD Cowen, William Blair, H.C. Wainwright & Co., and Craig-Hallum.

Risks

• The closing of the offering is subject to customary closing conditions, which may not be met.
• Clinical trials are lengthy and expensive with uncertain outcomes, and results of earlier studies may not predict future results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
• There are uncertainties of government or third-party payer reimbursement.
• The company faces substantial competition and risks related to patent protection and litigation.

Future Outlook

The company intends to use the net proceeds from the offering to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer and for working capital and other general corporate purposes.

Management Comments

• The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors.

Industry Context

This offering is a common method for clinical-stage biotechnology companies to raise capital to fund research and development activities. The participation of new and existing investors suggests confidence in the company's pipeline and strategy.

Comparison to Industry Standards

• The use of an underwritten offering is a standard practice for biotech companies seeking to raise capital.
• The involvement of multiple book-runners and managers is typical for offerings of this size.
• The stated use of proceeds for clinical trials and working capital is consistent with industry norms for companies at this stage of development.
• The 6% underwriting discount is within the typical range for similar offerings.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and ability to fund research and development.
• Customers (patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The offering is expected to close on or about December 11, 2024.
• The company will use the net proceeds to fund clinical trials for onvansertib and for general corporate purposes.

Key Dates

Keywords

Cardiff Oncology, underwritten offering, common stock, clinical trials, onvansertib, metastatic colorectal cancer, capital raise, biotechnology, PLK1 inhibition, TD Securities, William Blair, H.C. Wainwright, Craig-Hallum